Inhalation devices for long-acting β₂-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD

References

• Roche N, Huchon GJ. Rationale for the choice of an aerosol delivery system. J Aerosol Med 2000;13:393–404
   PubMedGoogle Scholar
• British Thoracic Society Nebulizer Project Group. Nebulizer therapy. Guidelines. Thorax 1997;52(Suppl. 2):S4–S24
   Google Scholar
• Liard R, Zureik M, Aubier M, et al. Misuse of pressurized metered-dose inhalers by asthmatic patients treated in French private practice. Rev Epidemiol Sante Publique 1995;43:242–9
   PubMed Web of Science ®Google Scholar
• Roche N, Chinet T, Huchon G. Ambulatory inhalation therapy in obstructive lung diseases. Respiration 1997;64:121–30
   Google Scholar
• Broeders ME, Molema J, Hop WC, Folgering HT. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med 2003;16:131–41
   PubMedGoogle Scholar
• Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16:249–54
   PubMedGoogle Scholar
• Ross DL, Gabrio BJ. Advances in metered dose inhaler technology with the developments of a CFC-free drug delivery system. J Aerosol Med 1999;12:151–60
   PubMedGoogle Scholar
• McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers – into the new millennium. Int J Pharm 2000;201:89–107
   PubMed Web of Science ®Google Scholar
• Ashurst I, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today 2000;3:246–56
   PubMedGoogle Scholar
• Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002;96:293–304
   PubMed Web of Science ®Google Scholar
• Smith IJ. The challenge of reformulation. J Aerosol Med 1995;8(Suppl. 1):S19–S27
   Google Scholar
• Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000;94(Suppl. B):S3–S9
   Google Scholar
• Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999;12(Suppl. 1):S9–S17
   Google Scholar
• Wallin A, Sandstrom T, Rosenhall L, Melander B. Time course and duration of action of bronchodilation with formoterol dry powder in patients with stable asthma. Thorax 1993;48:611–4
   PubMed Web of Science ®Google Scholar
• Dolovich M. Influence of respiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care 2000;45:597–608
   PubMedGoogle Scholar
• Clark AR. Medical aerosol inhalers: past, present and future. Aerosol Sci Technol 1995;22:374–91
   Web of Science ®Google Scholar
• Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers – implications for in vitro testing. J Aerosol Med 1993;6:99–110
   PubMedGoogle Scholar
• Timsina M, Martin GP, Marriott C, et al. Studies on the effects of dry powder inhalers upon peak inspiratory flow (PIF) in volunteers. J Aerosol Med 1993;6(Suppl.):1053
   Google Scholar
• de Koning JP, van der Mark ThW, Coenegracht PMJ, et al. Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm 2002;234:257–66
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): US Dept of Health and Human Services, Public Health Service; 1998 [NIH publication No. 98–4051]
   Google Scholar
• Engel T, Heinig JH, Madsen F, Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur Respir J 1990;3:1037–41
   PubMed Web of Science ®Google Scholar
• Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990;65:308–10
   Google Scholar
• Clark AR. Effect of powder inhaler resistance upon inspiratory profiles in health and disease. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery IV. Buffalo Grove: Interpharm Press; 1994. p. 117–24
   Google Scholar
• Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 1998;7:73–80
   Google Scholar
• Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med 1994;7(Suppl. 1):S43–S47
   Google Scholar
• Chege JK, Chrystyn H. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation. Respir Med 2000;94:51–6
   PubMed Web of Science ®Google Scholar
• Weuthen T, Roeders S, Brand P, et al. In vitro testing of formoterol dry powder inhalers at different flow rates. J Aerosol Med 2002;15:297–303
   PubMedGoogle Scholar
• Novartis Pharma AG, data on file
   Google Scholar
• Ganderton D, Byron PR. Harmonising inhaler testing across the pharmacopoeias. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996. p. 283–92
   Google Scholar
• Malton A, Sumby BS, Smith IJ. A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur J Clin Res 1995;7:177–93
   Google Scholar
• Meakin BJ, Dimond P, Lee D. Bricanyl Turbuhaler, Serevent Accuhaler and Foradil Aerolizer: comparative drug delivery. Thorax 1996;51(Suppl. B):A73
   Google Scholar
• Bronsky EA, Grossman J, Henis MMJ, et al. Inspiratory flow rates and volumes with the Aerolizer dry power inhaler in asthmatic children and adults. Curr Med Res Opin 2004;20:131–7
   PubMed Web of Science ®Google Scholar
• Krummen M, Singh D, Fiebich K, Haeberlin B. Flow-dependent performance of several formoterol dry powder inhalers (DPIs). Eur Respir J 2006(Suppl.):435s [abstract]
   Google Scholar
• Nana A, Youngchaiyud P, Maranetra N, et al. b2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med 1998;92:167–72
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med 2005;172: 1497–504
   Google Scholar
• Chew NY, Chan HK. In vitro aerosol performance and dose uniformity between the Foradil Aerolizer and the Oxis Turbuhaler. J Aerosol Med 2001;14:495–501
   PubMedGoogle Scholar
• Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995;116:169–77
   Web of Science ®Google Scholar
• FDA. Guidance for industry. Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), October 1998. Available at: http://www.fda.gov/cder/guidance/2180dft.pdf [Last accessed 2 October 2006]
   Google Scholar
• Criée CP, Meyer T, Petro W, et al. In vitro comparison of two delivery devices for administering formoterol: Foradil^® P and formoterol ratiopharm single-dose capsule inhaler. J Aerosol Med 2006;19:466–72
   Google Scholar
• Jackson C, Lipworth B. Optimizing inhaled drug delivery in patients with asthma. Br J Gen Pract 1995;45:683–7
   PubMed Web of Science ®Google Scholar
• Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000;94:496–500
   Google Scholar
• Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000;117:542–50
   PubMed Web of Science ®Google Scholar
• Crompton GK. The adult patient’s difficulties with inhalers. Lung 1990;168(Suppl.):658–62
   Google Scholar
• Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002;19:246–51
   PubMed Web of Science ®Google Scholar
• Clauzel A-M, Molimard M, Le Gros V, et al. Use of formoterol dry powder administered for three months via a single dose inhaler in 1380 asthmatic patients. J Investig Allergol Clin Immunol 1998;8: 265–70
   Google Scholar
• Girodet PO, Raherison C, Abouelfath A, et al. Real-life use of inhaler devices for chronic obstructive pulmonary disease in primary care. Therapie 2003;58:499–504
   PubMed Web of Science ®Google Scholar
• van der Palen J, Klein JJ, van Herwaarden CL, et al. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034–7
   PubMed Web of Science ®Google Scholar
• Fiocchi A, Terracciano L, Arrigoni S, Bonvini G. Device preference and efficacy of formoterol Aerolizer and salbutamol MDI in children with asthma. Eur Respir J 2003;22(Suppl. 45):134s [abstract P888]
   Google Scholar
• Pearlman DS, Kottakis J, Till D, Della Cioppa G. Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children. Curr Med Res Opin 2002;18:445–55
   Google Scholar
• Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol 2004;93:439–46
   PubMed Web of Science ®Google Scholar
• Maesen FPV. Long lasting treatment of stable moderately severe asthma patients with formoterol alone does not lead to desensitization. Eur Respir J 1994;7(Suppl. 18):110S
   Google Scholar
• Vervloet D, Ekstrom T, Pela R, et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 1998;92:836–42
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol 1999;103:427–35
   PubMed Web of Science ®Google Scholar
• Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002;89:180–90
   PubMed Web of Science ®Google Scholar
• Thomson NC, Angus R, Quebe-Fehling E, Brambilla R. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir Med 1998;92:562–7
   Google Scholar
• Hacki MA, Hinz GW, Medici TC. Clinical experience over 5 years of daily therapy with formoterol in patients with bronchial asthma. Clin Drug Invest 1997;14: 165–74
   Google Scholar
• Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778–84
   PubMed Web of Science ®Google Scholar
• Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058–69
   PubMed Web of Science ®Google Scholar
• Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001;86:19–27
   PubMed Web of Science ®Google Scholar
• Pleskow W, LaForce CF, Yegen U, et al. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma 2003;40:505–14
   PubMed Web of Science ®Google Scholar
• Benhamou D, Cuvelier A, Muir JF, et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001;95:817–21
   PubMed Web of Science ®Google Scholar
• Richter K, Stenglein S, Mucke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006;73:414–9
   PubMed Web of Science ®Google Scholar
• Steffensen I, Faurschon P, Riska H, et al. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airways disease. Allergy 1995;50:657–63
   PubMed Web of Science ®Google Scholar
• Jones PW, Brambilla R, Till MD. Quality of life in patients treated with two long-acting b2-agonists: formoterol (Foradil) and salmeterol (Serevent). J Allergy Clin Immunol 1998;101:S186–S187 [abstract]
   Google Scholar
• Molimard M, Bourcereau J, Le Gros V, et al. Comparison between formoterol 12 µg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respir Med 2001;95:64–70
   Google Scholar
• Lotvall J, Mellen A, Ardvisson P, et al. Similar bronchodilation with formoterol delivered by AerolizerÒ or TurbuhalerÒ. Can Respir J 1999;6:412–6
   PubMedGoogle Scholar
• Eliraz A, Ramirez-Rivera A, Ferranti P, et al. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 mg b.i.d. delivered by two different dry powder inhalers; differences in inhaler handling. Int J Clin Pract 2001;55:164–70
   Google Scholar
• Schlimmer P. Single-dose comparison of formoterol (Oxis) Turbuhaler 6 mg and formoterol Aerolizer 12 mg in moderate to severe asthma: a randomised, crossover study. Pulm Pharmacol Ther 2002;15:369–74
   PubMed Web of Science ®Google Scholar
• Otto-Knapp R, Conrad F, Hosch S, et al. Efficacy and safety of formoterol delivered through the Novolizer®, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma. Pulm Pharmacol Ther 2006 December 14; [Epub ahead of print]
   Google Scholar
• Dubakiene R, Nargela R, Sakalauskas R, et al. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer. Respiration 2006;73:441–8
   PubMed Web of Science ®Google Scholar
• Randell J, Saarinen A, Walamies M, et al. Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer. Respir Med 2005;99:1485–93
   PubMed Web of Science ®Google Scholar
• Houghton CM, Langley SJ, Singh SD, et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 2004;58:359–66
   PubMed Web of Science ®Google Scholar
• Bousquet J, Huchon G, Leclerc V, et al. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration 2005;72(Suppl 1):6–12
   PubMedGoogle Scholar
• Bousquet J, Guenole E, Duvauchelle T, et al. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 µg) of formoterol-HFA (pMDI) vs. those of a dose level (24 µg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients. Respiration 2005;72(Suppl 1):13–9
   Google Scholar
• Lipworth BJ, Sims EJ, Das SK, et al. Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. Ann Allergy Asthma Immunol 2005;95:283–90
   PubMed Web of Science ®Google Scholar
• Dahl R, Creemers JP, Van Noord J, et al. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration 2004;71:126–33
   PubMed Web of Science ®Google Scholar
• Chuchalin AG, Manjra AI, Rozinova NN, et al. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma. J Aerosol Med 2005;18:63–73
   PubMedGoogle Scholar